OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M. Kerr, et al.
Lung Cancer (2023) Vol. 184, pp. 107293-107293
Open Access | Times Cited: 43
Tony Kiat Hon Lim, Ferdinandos Skoulidis, Keith M. Kerr, et al.
Lung Cancer (2023) Vol. 184, pp. 107293-107293
Open Access | Times Cited: 43
Showing 1-25 of 43 citing articles:
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology
Juan Carlos Laguna, Miguel García-Pardo, Joao V. Alessi, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 11
Juan Carlos Laguna, Miguel García-Pardo, Joao V. Alessi, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 11
Efficacy and Safety of KRAS G12C Inhibitor IBI351 Monotherapy in Patients With Advanced NSCLC: Results From a Phase 2 Pivotal Study
Qing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. 1630-1639
Closed Access | Times Cited: 10
Qing Zhou, Xiangjiao Meng, Longhua Sun, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 12, pp. 1630-1639
Closed Access | Times Cited: 10
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 8
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review
Mohammad Saleh Sadeghi, Mohadeseh lotfi, Narges Soltani, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Mohammad Saleh Sadeghi, Mohadeseh lotfi, Narges Soltani, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
Solange Peters, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 76-93
Open Access | Times Cited: 7
Solange Peters, Byoung Chul Cho, Alexander Luft, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 76-93
Open Access | Times Cited: 7
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
Samir H. Barghout, Luna Jia Zhan, Starvroula Raptis, et al.
Lung Cancer (2024) Vol. 194, pp. 107898-107898
Closed Access | Times Cited: 6
Samir H. Barghout, Luna Jia Zhan, Starvroula Raptis, et al.
Lung Cancer (2024) Vol. 194, pp. 107898-107898
Closed Access | Times Cited: 6
Targeted therapy of non-small cell lung cancer: mechanisms and clinical trials
Le Yu, Ruoyi Yang, Long Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Le Yu, Ruoyi Yang, Long Zeng, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 6
Molecular pathology of non‐small cell carcinoma
Yasushi Yatabe
Histopathology (2023) Vol. 84, Iss. 1, pp. 50-66
Open Access | Times Cited: 13
Yasushi Yatabe
Histopathology (2023) Vol. 84, Iss. 1, pp. 50-66
Open Access | Times Cited: 13
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Judit Moldvay, József Tı́már
Pathology & Oncology Research (2024) Vol. 29
Open Access | Times Cited: 5
Judit Moldvay, József Tı́már
Pathology & Oncology Research (2024) Vol. 29
Open Access | Times Cited: 5
Advancements in NSCLC
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
Jianan Xu, Lin Tian, Wenlong Qi, et al.
American Journal of Clinical Oncology (2024)
Open Access | Times Cited: 5
Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer
Huiping Qiang, Yue Wang, Yao Zhang, et al.
Translational Oncology (2025) Vol. 53, pp. 102317-102317
Open Access
Huiping Qiang, Yue Wang, Yao Zhang, et al.
Translational Oncology (2025) Vol. 53, pp. 102317-102317
Open Access
SUPRACLAVICULAR LYMPH NODE METASTASES IN ADVANCED LUNG CANCER: PREVALENCE AND ANALYSIS OF DEMOGRAPHIC, CLINICAL AND MOLECULAR CHARACTERISTICS
Rocco Trisolini, Valeria Cetoretta, Giovanni Sotgiu, et al.
Clinical Lung Cancer (2025)
Closed Access
Rocco Trisolini, Valeria Cetoretta, Giovanni Sotgiu, et al.
Clinical Lung Cancer (2025)
Closed Access
Phosphorylation of POU3F3 Mediated Nuclear Translocation Promotes Proliferation in Non‐Small Cell Lung Cancer through Accelerating ATP5PF Transcription and ATP Production
Qigang Zeng, Le Li, Tao Chang, et al.
Advanced Science (2025)
Open Access
Qigang Zeng, Le Li, Tao Chang, et al.
Advanced Science (2025)
Open Access
Second-line therapy for KRAS-positive metastatic non-small cell lung cancer
Martin Svatoň
Onkologie (2025) Vol. 19, Iss. 1, pp. 29-32
Closed Access
Martin Svatoň
Onkologie (2025) Vol. 19, Iss. 1, pp. 29-32
Closed Access
Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report
Antonio Vitale, Emanuele Vita, Alessio Stefani, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
Antonio Vitale, Emanuele Vita, Alessio Stefani, et al.
The Oncologist (2025) Vol. 30, Iss. 3
Open Access
RASON promotes KRASG12C-driven tumor progression and immune evasion in non-small cell lung cancer
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Jianzhuang Wu, Kexin Xie, Yixuan Zhang, et al.
Journal of Experimental & Clinical Cancer Research (2025) Vol. 44, Iss. 1
Open Access
Lung Adenocarcinoma Exhibiting Thanatosomes (Hyaline Bodies), Cytoplasmic Clearing, and Nuclear Pleomorphism, with a KRAS Mutation
Mitsuhiro Tachibana, Yutaro Ito, Ryo Fujikawa, et al.
Diagnostics (2025) Vol. 15, Iss. 7, pp. 894-894
Open Access
Mitsuhiro Tachibana, Yutaro Ito, Ryo Fujikawa, et al.
Diagnostics (2025) Vol. 15, Iss. 7, pp. 894-894
Open Access
Targeting KRAS-G12C in Lung Cancer: The Emerging Role of PROTACs in Overcoming Resistance
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
Kumarappan Chidambaram, Arcot Rekha, Ahsas Goyal, et al.
Pathology - Research and Practice (2025), pp. 155954-155954
Closed Access
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
R. Rosell, Jordi Codony‐Servat, Jessica González, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 195, pp. 104228-104228
Open Access | Times Cited: 12
Precision medicine for pancreatic cancer: Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease
Fergus Keane, Joanne F. Chou, Henry Walch, et al.
JNCI Journal of the National Cancer Institute (2024) Vol. 116, Iss. 9, pp. 1429-1438
Closed Access | Times Cited: 2
Fergus Keane, Joanne F. Chou, Henry Walch, et al.
JNCI Journal of the National Cancer Institute (2024) Vol. 116, Iss. 9, pp. 1429-1438
Closed Access | Times Cited: 2
KRAS depletion suppresses ferroptosis and affects Hippo pathway in cataract
Hongda Jiang, Yinggui Yu, Yu Yan
General Physiology and Biophysics (2024) Vol. 43, Iss. 03, pp. 243-253
Open Access | Times Cited: 2
Hongda Jiang, Yinggui Yu, Yu Yan
General Physiology and Biophysics (2024) Vol. 43, Iss. 03, pp. 243-253
Open Access | Times Cited: 2
Current status of molecular diagnostics for lung cancer
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, С. В. Орлов
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 742-765
Open Access | Times Cited: 2
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, С. В. Орлов
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 3, pp. 742-765
Open Access | Times Cited: 2
p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications
Dixan A. Benitez, Guadalupe Cumplido-Laso, Marcos Olivera-Gómez, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1453-1453
Open Access | Times Cited: 2
Dixan A. Benitez, Guadalupe Cumplido-Laso, Marcos Olivera-Gómez, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1453-1453
Open Access | Times Cited: 2
